2020 American Transplant Congress
De Novo Dosing of LCP-Tacrolimus Using Conservative Weight-Based Strategy Resulted in Supratherapeutic Trough Levels in Majority of Patients
University of Virginia Health System, Charlottesville, VA
*Purpose: Due to ongoing national drug shortages, our center transitioned to de novo use of LCP-tacrolimus (LCPT) in kidney transplant patients using a conservative dosing…2020 American Transplant Congress
De Novo Dosing and Trough Attainment Trends of Extended-Release Tacrolimus in the Absence of Dose Adjustments
*Purpose: Initial dosing of tacrolimus extended-release tablets (LCPT) was 0.17 mg/kg/day in the pivotal trial in de novo kidney transplant recipients. Dosing subsequent to the…2020 American Transplant Congress
Safety and Efficacy of Valganciclovir for Cytomegalovirus Prophylaxis in Solid Organ Transplant Patients on Hemodialysis
Houston Methodist Hospital, Houston, TX
*Purpose: Cytomegalovirus (CMV) is the most common viral infection after solid organ transplant (SOT) and is associated with significant morbidity and mortality. Valganciclovir (VGCV) is…2020 American Transplant Congress
Exposure to Tacrolimus Trough Levels Below 6ng/ml During the First Year is Associated with Inferior Kidney Graft Survival
Department of Nephrology and Hypertension, Rabin Medical Center, Petah Tikva, Israel
*Purpose: Accumulating data indicates that sub-therapeutic levels of calcineurin inhibitors are associated with long-term graft loss. However, while widely used tacrolimus (TAC) was shown to…2020 American Transplant Congress
Comparing Weight-Based Dosing of Envarsus XR in Obese and Non-Obese Renal Transplant Recipients
North Shore University Hospital, Manhasset, NY
*Purpose: Tacrolimus has a narrow therapeutic window and significant inter- and intra-patient variability leading to variations in drug concentration. The recommended initial weight-based dose of…2020 American Transplant Congress
Assessment of Time to Therapeutic Tacrolimus Levels Following Renal Transplantation in a Non-Weight-Based Dosing Model
*Purpose: The optimal initial dose for tacrolimus (TAC) after renal transplant (RT) remains controversial with limited evidence comparing weight-based and conservative strategies. Recent literature suggests…2020 American Transplant Congress
Less Bleeding Associated with Apixaban versus Other Direct Acting Oral Anticoagulation in Solid Organ Transplant Recipients
*Purpose: Owing to their fixed dosing and favorable drug interaction profiles, direct acting oral anticoagulants (DOACs) have supplanted warfarin as the standard of care for…2020 American Transplant Congress
A Single Centre Experience of Conversion from Immediate Release Tacrolimus (IR-tac) to Extended Release Envarsus
*Purpose: IR-Tac is first line maintenance immunosuppression in kidney transplant recipients. Its rapid absorption of 1-2 hours can lead to peak levels (Tmax ) within…2019 American Transplant Congress
Not All Poor Metabolizers Are Clinically Equal: Evaluating Weight-Based Tacrolimus Outcomes in CYP3A Loss of Function Variants
Vidant Medical Center - Transplant Services, Greenville, NC
*Purpose: CYP3A polymorphisms are an important pharmacotherapeutic consideration due to the extensive CYP metabolism of tacrolimus (TAC) and variable expression among different races. The CPIC…2019 American Transplant Congress
Dosing Requirements Of Astagraf Xl In African American Kidney Transplant Recipients Converted From Twice-daily Tacrolimus (aaaktrs)
Medical University of South Carolina, Charleston, SC
*Purpose: Pharmacokinetics from clinical studies demonstrated similar drug exposure (AUC) and correlation between trough (C0) and AUC between tacrolimus IR and Astagraf XL, which led…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »